These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23340167)

  • 1. Meta-analysis: serious adverse events in Crohn's disease patients treated with TNF-alpha inhibitors.
    Zhang D; Xiong B; Li X; Xu T; Yu M
    Hepatogastroenterology; 2013 Sep; 60(126):1333-42. PubMed ID: 23340167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
    Riis A; Martinsen TC; Waldum HL; Fossmark R
    Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS; Nelson M; Dolder CR
    Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti tumour necrosis factor as risk factor for free perforations in Crohn's disease? A case-control study.
    Eshuis EJ; Griffioen GH; Stokkers PC; Ubbink DT; Bemelman WA
    Colorectal Dis; 2012 May; 14(5):578-84. PubMed ID: 21848898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.
    Papamichael K; Mantzaris GJ; Peyrin-Biroulet L
    Expert Opin Drug Saf; 2016; 15(4):493-501. PubMed ID: 26799429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
    Hanauer SB; Sandborn WJ; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh D; Panaccione R; Wolf D; Pollack P
    Gastroenterology; 2006 Feb; 130(2):323-33; quiz 591. PubMed ID: 16472588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
    Tan X; Balkrishnan R; Feldman SR
    J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.
    Askling J; Fahrbach K; Nordstrom B; Ross S; Schmid CH; Symmons D
    Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):119-30. PubMed ID: 21254282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
    Osterman MT; Sandborn WJ; Colombel JF; Robinson AM; Lau W; Huang B; Pollack PF; Thakkar RB; Lewis JD
    Gastroenterology; 2014 Apr; 146(4):941-9. PubMed ID: 24361468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.
    Melmed GY; Spiegel BM; Bressler B; Cheifetz AS; Devlin SM; Harrell LE; Irving PM; Jones J; Kaplan GG; Kozuch PL; Velayos FS; Baidoo L; Sparrow MP; Siegel CA
    Clin Gastroenterol Hepatol; 2010 Aug; 8(8):655-9. PubMed ID: 20451665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adalimumab in Crohn's disease: meta-analysis of placebo-controlled trials.
    Huang ML; Ran ZH; Shen J; Li XB; Xu XT; Xiao SD
    J Dig Dis; 2011 Jun; 12(3):165-72. PubMed ID: 21615869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.
    Marehbian J; Arrighi HM; Hass S; Tian H; Sandborn WJ
    Am J Gastroenterol; 2009 Oct; 104(10):2524-33. PubMed ID: 19532125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
    Shao LM; Chen MY; Cai JT
    Aliment Pharmacol Ther; 2009 Mar; 29(6):605-14. PubMed ID: 19183161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
    Feagan BG; Panaccione R; Sandborn WJ; D'Haens GR; Schreiber S; Rutgeerts PJ; Loftus EV; Lomax KG; Yu AP; Wu EQ; Chao J; Mulani P
    Gastroenterology; 2008 Nov; 135(5):1493-9. PubMed ID: 18848553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.